Q-omics provides the consensus-scored C8orf37 profile across patient tissues and cancer cell-line models. C8orf37 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C8orf37 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, C8orf37 RNA expression shows 20,175 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where C8orf37 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C8orf37 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C8orf37 survival associations across molecular data types. C8orf37 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C8orf37 RNA expression–survival associations across cancer types. High C8orf37 expression shows unfavorable associations in UVM, MESO and LUAD, but favorable associations in KIRC, BRCA and OV. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C8orf37 RNA expression.
This table summarizes C8orf37 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for C8orf37. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C8orf37 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, COAD and CHOL. The THCA box plot shows higher C8orf37 RNA expression in normal versus tumor tissue (log2 FC = −0.736, t-test p < 0.001).
This table shows molecular features associated with C8orf37 in patient tissues and cancer cell lines. In patient samples, C8orf37 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C8orf37 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
